Alicia J Jenkins

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7460105/publications.pdf

Version: 2024-02-01

343 papers 14,245 citations

20817 60 h-index 101 g-index

347 all docs

347 docs citations

times ranked

347

16204 citing authors

#	Article	IF	CITATIONS
1	Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: A prospective cohort study from the Hong Kong diabetes biobank. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 436-446.	2.6	11
2	A Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type 1 Diabetes. Diabetes Care, 2022, 45, 194-203.	8.6	24
3	Global accessibility of therapeutics for diabetes mellitus. Nature Reviews Endocrinology, 2022, 18, 199-204.	9.6	38
4	Shortened Leukocyte Telomere Length Is Associated With Glycemic Progression in Type 2 Diabetes: A Prospective and Mendelian Randomization Analysis. Diabetes Care, 2022, 45, 701-709.	8.6	37
5	Healthâ€risk behaviours among Indigenous Australians with diabetes: A study in the integrated Diabetes Education and Eye Screening (iDEES) project. Journal of Advanced Nursing, 2022, 78, 1305-1316.	3.3	4
6	Mixed diabetic retinopathy screening coverage results in Indigenous Australian primary care settings: A nurseâ€led model of integrated diabetes care. Journal of Advanced Nursing, 2022, 78, 3187-3196.	3.3	4
7	Lipids, hyperreflective crystalline deposits and diabetic retinopathy: potential systemic and retinal-specific effect of lipid-lowering therapies. Diabetologia, 2022, 65, 587-603.	6.3	15
8	Upload and Review of Insulin Pump and Glucose Sensor Data by Adults with Type 1 Diabetes: A Clinic Audit. Diabetes Technology and Therapeutics, 2022, 24, 531-534.	4.4	2
9	Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. Diabetes Technology and Therapeutics, 2022, 24, 350-356.	4.4	1
10	Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy. Diabetes Research and Clinical Practice, 2022, 186, 109835.	2.8	1
11	Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register. Diabetologia, 2022, 65, 375-386.	6.3	11
12	Multifocal pupillographic objective perimetry for assessment of early diabetic retinopathy and generalised diabetes-related tissue injury in persons with type 1 diabetes. BMC Ophthalmology, 2022, 22, 166.	1.4	2
13	Fenofibrate, which reduces risk of sightâ€threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a <scp>FIELD</scp> trial substudy. Internal Medicine Journal, 2022, 52, 676-679.	0.8	2
14	Nurseâ€led vascular risk assessment in a regional Victorian Indigenous primary care diabetes clinic: An integrated Diabetes Education and Eye disease Screening [<scp>iDEES</scp>] study. Journal of Advanced Nursing, 2022, , .	3.3	2
15	Telomeres do not always shorten over time in individuals with type 1 diabetes. Diabetes Research and Clinical Practice, 2022, $188,109926.$	2.8	3
16	Vitamin D Levels During Pregnancy Are Associated With Offspring Telomere Length: A Longitudinal Mother-Child Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3901-e3909.	3.6	1
17	Skin autofluorescence in people with type 1 diabetes and people without diabetes: An eightâ€decade crossâ€sectional study with evidence of accelerated aging and associations with complications. Diabetic Medicine, 2021, 38, e14432.	2.3	8
18	Screening for diabetic retinopathy and reduced vision among Indigenous Australians in Top End primary care health services: a ⟨scp⟩TEAMSnet⟨/scp⟩ subâ€study. Internal Medicine Journal, 2021, 51, 1897-1905.	0.8	2

#	Article	IF	Citations
19	Imaging the eye and its relevance to diabetes care. Journal of Diabetes Investigation, 2021, 12, 897-908.	2.4	5
20	Diabetes, metabolic disease, and telomere length. Lancet Diabetes and Endocrinology,the, 2021, 9, 117-126.	11.4	98
21	Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 32-45.	11.4	164
22	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. Diabetes Technology and Therapeutics, 2021, 23, 460-466.	4.4	7
23	20â€year outcomes of childhoodâ€onset type 1 diabetes: The CANDID incident cohort survey. Diabetic Medicine, 2021, 38, e14473.	2.3	0
24	Shortened relative leukocyte telomere length is associated with all-cause mortality in type 2 diabetes-analysis from the Hong Kong Diabetes Register. Diabetes Research and Clinical Practice, 2021, 173, 108649.	2.8	10
25	Metformin and carotid intimaâ€media thickness in neverâ€smokers with type <scp>1</scp> diabetes: The <scp>REMOVAL</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1371-1378.	4.4	11
26	Facilitating diabetic retinopathy screening using automated retinal image analysis in underresourced settings. Diabetic Medicine, 2021, 38, e14582.	2.3	6
27	Insulin micro-secretion in Type 1 diabetes and related microRNA profiles. Scientific Reports, 2021, 11, 11727.	3.3	16
28	The relationship of neutrophil elastase and proteinase 3 with risk factors, and chronic complications in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) sub-study. Diabetes and Vascular Disease Research, 2021, 18, 147916412110325.	2.0	3
29	Associations with sight-threatening diabetic macular oedema among Indigenous adults with type 2 diabetes attending an Indigenous primary care clinic in remote Australia: a Centre of Research Excellence in Diabetic Retinopathy and Telehealth Eye and Associated Medical Services Network study. BMI Open Ophthalmology, 2021, 6, e000559.	1.6	3
30	Serum urate and cardiovascular events in the DCCT/EDIC study. Scientific Reports, 2021, 11, 14182.	3.3	2
31	First Randomized Controlled Trial of Hybrid Closed Loop Versus Multiple Daily Injections or Insulin Pump Using Self-Monitoring of Blood Glucose in Free-Living Adults with Type 1 Diabetes Undertaking Exercise. Journal of Diabetes Science and Technology, 2021, 15, 1399-1401.	2.2	9
32	Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes. Scientific Reports, 2021, 11, 16656.	3.3	1
33	Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. Diabetes Care, 2021, 44, 2371-2378.	8.6	22
34	Baseline extended zone retinal vascular calibres associate with sensory nerve abnormalities in adolescents with type 1 diabetes: A prospective longitudinal study. Diabetic Medicine, 2021, 38, e14662.	2.3	1
35	Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 2021, 11, 18708.	3.3	1
36	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. Diabetes Research and Clinical Practice, 2021, 179, 109000.	2.8	3

#	Article	IF	Citations
37	Skin autofluorescence is associated with higher risk of cardiovascular events in Chinese adults with type 2 diabetes: A prospective cohort study from the Hong Kong Diabetes Biobank. Journal of Diabetes and Its Complications, 2021, 35, 108015.	2.3	9
38	A model of culturallyâ€informed integrated diabetes education and eye screening in indigenous primary care services and specialist diabetes clinics: Study protocol. Journal of Advanced Nursing, 2021, 77, 1578-1590.	3.3	6
39	Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes. JAMA Pediatrics, 2021, 175, 1227.	6.2	54
40	Prevalence of diabetic retinopathy and reduced vision among Indigenous Australians in the nurseâ€led iDEES study in a regional primary care clinic. Internal Medicine Journal, 2021, , .	0.8	0
41	Costâ€effectiveness of professionalâ€mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GPâ€OSMOTIC trial. Diabetic Medicine, 2021, , e14747.	2.3	1
42	Short-term glucose variability in adults with Type 1 diabetes does not differ between insulin pump and multiple daily injection users $\hat{a} \in \hat{a}$ a masked continuous glucose monitoring study in clinical practice. Diabetes and Metabolism, 2020, 46, 172-174.	2.9	2
43	Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 17-26.	11.4	30
44	Glucose and Counterregulatory Responses to Exercise in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia Using Closed-Loop Insulin Delivery: A Randomized Crossover Study. Diabetes Care, 2020, 43, 480-483.	8.6	19
45	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. Diabetes Care, 2020, 43, 3024-3033.	8.6	85
46	Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study. Diabetes Research and Clinical Practice, 2020, 169, 108450.	2.8	6
47	Estimated insulin sensitivity in Type 1 diabetes adults using clinical and research biomarkers. Diabetes Research and Clinical Practice, 2020, 167, 108359.	2.8	12
48	Extended-Zone Retinal Vascular Caliber and Risk of Diabetic Retinopathy in Adolescents with Type 1 Diabetes. Ophthalmology Retina, 2020, 4, 1151-1157.	2.4	2
49	Shortened Relative Leukocyte Telomere Length Is Associated With Prevalent and Incident Cardiovascular Complications in Type 2 Diabetes: Analysis From the Hong Kong Diabetes Register. Diabetes Care, 2020, 43, 2257-2265.	8.6	31
50	Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3638-e3649.	3.6	37
51	Vitamin D Metabolites and Binding Protein Predict Preeclampsia in Women with Type 1 Diabetes. Nutrients, 2020, 12, 2048.	4.1	4
52	Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC trial. Diabetes Research and Clinical Practice, 2020, 169, 108451.	2.8	2
53	FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. Scientific Reports, 2020, 10, 21655.	3.3	17
54	COVID-19, Type 1 Diabetes Clinical Practice, Research, and Remote Medical Care: A View From the Land Down-Under. Journal of Diabetes Science and Technology, 2020, 14, 803-804.	2.2	11

#	Article	IF	CITATIONS
55	Diabetes and COVID-19: IDF perspective in the Western Pacific region. Diabetes Research and Clinical Practice, 2020, 166, 108278.	2.8	7
56	Challenges of diabetes management during the <code><scp>COVID</scp></code> $\hat{a}\in 19$ pandemic. Medical Journal of Australia, 2020, 213, 56.	1.7	34
57	Adults With Diabetes Distress Often Want to Talk With Their Health Professionals About It: Findings From an Audit of 4 Australian Specialist Diabetes Clinics. Canadian Journal of Diabetes, 2020, 44, 473-480.	0.8	26
58	Circulating branchedâ€chain amino acids and incident heart failure in type 2 diabetes: The Hong Kong Diabetes Register. Diabetes/Metabolism Research and Reviews, 2020, 36, e3253.	4.0	20
59	Uric acid predicts <scp>longâ€ŧerm</scp> cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The <scp>FIELD</scp> study. Diabetes, Obesity and Metabolism, 2020, 22, 1388-1396.	4.4	6
60	Author reply. Internal Medicine Journal, 2020, 50, 507-508.	0.8	1
61	Pointâ€ofâ€care testing of HbA1c , renal function and lipids in remote or disadvantaged regions. Internal Medicine Journal, 2020, 50, 1567-1571.	0.8	2
62	Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study. Diabetes Technology and Therapeutics, 2019, 21, 499-506.	4.4	25
63	Serum pigment epithelium-derived factor: Relationships with cardiovascular events, renal dysfunction, and mortality in the Veterans Affairs Diabetes Trial (VADT) cohort. Journal of Diabetes and Its Complications, 2019, 33, 107410.	2.3	4
64	Suggested clinical approach for the diagnosis and management of †statin intolerance†with an emphasis on muscle†elated side†effects. Internal Medicine Journal, 2019, 49, 1081-1091.	0.8	15
65	A high-volume, low-cost approach to participant screening and enrolment: Experiences from the T4DM diabetes prevention trial. Clinical Trials, 2019, 16, 589-598.	1.6	1
66	Associations between circulating inflammatory markers, diabetes type and complications in youth. Pediatric Diabetes, 2019, 20, 1118-1127.	2.9	31
67	Insulin Pumps: Review of Technological Advancement in Diabetes Management. American Journal of the Medical Sciences, 2019, 358, 326-331.	1.1	46
68	Continuous Glucose Monitoring: Review of an Innovation in Diabetes Management. American Journal of the Medical Sciences, 2019, 358, 332-339.	1.1	77
69	Haptoglobin Phenotype Modulates Lipoprotein-Associated Risk for Preeclampsia in Women With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4743-4755.	3.6	5
70	MicroRNA-Related Genetic Variants Are Associated With Diabetic Retinopathy in Type 1 Diabetes Mellitus., 2019, 60, 3937.		11
71	Mitochondrial haplogroups are not associated with diabetic retinopathy in a large Australian and British Caucasian sample. Scientific Reports, 2019, 9, 612.	3.3	2
72	Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. Journal of Lipid Research, 2019, 60, 1432-1439.	4.2	24

#	Article	IF	Citations
73	Telephone call reminders did not increase screening uptake more than SMS reminders: a recruitment study within a trial. Journal of Clinical Epidemiology, 2019, 112, 45-52.	5.0	4
74	Integrating diabetic retinopathy screening within diabetes education services in Australia's diabetes and indigenous primary care clinics. Internal Medicine Journal, 2019, 49, 797-800.	0.8	5
75	Prescribing of diabetes medications to people with type 2 diabetes and chronic kidney disease: a national cross-sectional study. BMC Family Practice, 2019, 20, 29.	2.9	10
76	Fenofibrate Rescues Diabetes-Related Impairment of Ischemia-Mediated Angiogenesis by PPARα-Independent Modulation of Thioredoxin-Interacting Protein. Diabetes, 2019, 68, 1040-1053.	0.6	22
77	Maternal stress during pregnancy and small for gestational age birthweight are not associated with telomere length at 11†years of age. Gene, 2019, 694, 97-101.	2.2	11
78	HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment. BMJ Open, 2019, 9, e033059.	1.9	16
79	Higher Serum Sex Hormone–Binding Globulin Levels Are Associated With Incident Cardiovascular Disease in Men. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6301-6315.	3.6	31
80	The early detection of atherosclerosis in type 1 diabetes: why, how and what to do about it. Cardiovascular Endocrinology and Metabolism, 2019, 8, 14-27.	1.1	18
81	High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). Metabolism: Clinical and Experimental, 2019, 93, 93-99.	3.4	24
82	Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2019, 21, 56-58.	4.4	22
83	The Clinical Case for the Integration of a Ketone Sensor as Part of a Closed Loop Insulin Pump System. Journal of Diabetes Science and Technology, 2019, 13, 967-973.	2.2	14
84	Management of Diabetes Mellitus. Contemporary Cardiology, 2019, , 113-177.	0.1	0
85	Testosterone therapy to prevent type 2 diabetes mellitus in atâ€risk men (T4DM): Design and implementation of a doubleâ€blind randomized controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 772-780.	4.4	25
86	Attractions and barriers to Australian physicianâ€researcher careers. Internal Medicine Journal, 2019, 49, 171-181.	0.8	12
87	38-LB: Discovery Analysis of MicroRNAs (miRs) Associated with Microvascular Complications in Adults with Type 1 Diabetes. Diabetes, 2019, 68, 38-LB.	0.6	1
88	Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes and Endocrinology, the, 2018, 6, 310-318.	11.4	43
89	Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. Internal Medicine Journal, 2018, 48, 1080-1086.	0.8	6
90	Impact of multimorbidity count on all-cause mortality and glycaemic outcomes in people with type 2 diabetes: a systematic review protocol. BMJ Open, 2018, 8, e021100.	1.9	5

#	Article	IF	Citations
91	Diastolic dysfunction is more apparent in STZ-induced diabetic female mice, despite less pronounced hyperglycemia. Scientific Reports, 2018, 8, 2346.	3.3	38
92	Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. Journal of Lipid Research, 2018, 59, 872-883.	4.2	8
93	Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes. Diabetes Care, 2018, 41, 120-127.	8.6	14
94	Associations between multimorbidity, all-cause mortality and glycaemia in people with type 2 diabetes: A systematic review. PLoS ONE, 2018, 13, e0209585.	2.5	32
95	Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. Lupus, 2018, 27, 2029-2040.	1.6	16
96	Response to Comment on Kelly et al. Subclinical First Trimester Renal Abnormalities Are Associated With Preeclampsia in Normoalbuminuric Women With Type 1 Diabetes. Diabetes Care 2018;41:120–127. Diabetes Care, 2018, 41, e102-e103.	8.6	0
97	Socioeconomic status and time in glucose target range in people with type 2 diabetes: a baseline analysis of the GP-OSMOTIC study. BMC Endocrine Disorders, 2018, 18, 47.	2.2	9
98	Cross-sectional and longitudinal determinants of serum sex hormone binding globulin (SHBG) in a cohort of community-dwelling men. PLoS ONE, 2018, 13, e0200078.	2.5	21
99	Genome-wide association studies for diabetic macular edema and proliferative diabetic retinopathy. BMC Medical Genetics, 2018, 19, 71.	2.1	49
100	Effect of a high-egg diet on cardiometabolic risk factors in people with type 2 diabetes: the Diabetes and Egg (DIABEGG) Studyâ€"randomized weight-loss and follow-up phase. American Journal of Clinical Nutrition, 2018, 107, 921-931.	4.7	34
101	Obesity, diabetes and zinc: A workshop promoting knowledge and collaboration between the UK and Israel, november 28–30, 2016 – Israel. Journal of Trace Elements in Medicine and Biology, 2018, 49, 79-85.	3.0	1
102	Metformin, lipids and atherosclerosis prevention. Current Opinion in Lipidology, 2018, 29, 346-353.	2.7	43
103	Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open, 2018, 8, e020274.	1.9	7
104	Factors associated with duration of inpatient hospital stay for patients with diabetes mellitus admitted to a medical unit in a community public hospital. Australian Journal of Primary Health, 2017, 23, 23.	0.9	3
105	Moving Toward a Unified Platform for Insulin Delivery and Sensing of Inputs Relevant to an Artificial Pancreas. Journal of Diabetes Science and Technology, 2017, 11, 308-314.	2.2	9
106	Asymmetric changes in circulating insulin levels after an increase compared with a reduction in insulin pump basal rate in people with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1158-1164.	2.3	2
107	Closed-Loop Insulin Delivery for Adults with Type 1 Diabetes Undertaking High-Intensity Interval Exercise Versus Moderate-Intensity Exercise: A Randomized, Crossover Study. Diabetes Technology and Therapeutics, 2017, 19, 340-348.	4.4	59
108	Overnight Counter-Regulatory Hormone Levels and Next Day Glycemia in Adults with Type 1 Diabetes During Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump with Low-Glucose Suspend. Diabetes Technology and Therapeutics, 2017, 19, 438-439.	4.4	0

#	Article	IF	Citations
109	"lt Is Definitely a Game Changer― A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 410-416.	4.4	28
110	Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 597-609.	11.4	248
111	Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clinical Chemistry, 2017, 63, 1261-1270.	3.2	11
112	An evaluation of the telehealth facilitation of diabetes and cardiovascular care in remote Australian Indigenous communities: - protocol for the telehealth eye and associated medical services network [TEAMSnet] project, a pre-post study design. BMC Health Services Research, 2017, 17, 13.	2.2	18
113	Severe hypoglycemia, impaired awareness of hypoglycemia, and self-monitoring in adults with type 1 diabetes: Results from Diabetes MILES—Australia. Journal of Diabetes and Its Complications, 2017, 31, 577-582.	2.3	27
114	Metformin in adults with type 1 diabetes: <scp>D</scp> esign and methods of <scp>REducing</scp> with <scp>MetfOrmin V</scp> ascular <scp>A</scp> dverse <scp>L</scp> esions (<scp>REMOVAL</scp>): <scp>A</scp> n international multicentre trial. Diabetes, Obesity and Metabolism, 2017, 19, 509-516.	4.4	32
115	Early changes of arterial elasticity in Type 1 diabetes with microvascular complications - A cross-sectional study from childhood to adulthood. Journal of Diabetes and Its Complications, 2017, 31, 1674-1680.	2.3	3
116	Triglyceride-lowering trials. Current Opinion in Lipidology, 2017, 28, 477-487.	2.7	12
117	Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes. Diabetologia, 2017, 60, 2514-2524.	6.3	21
118	Innovative technology shows impact of glycaemic control on peripheral retinal vessels in adolescents with type 1 diabetes. Diabetologia, 2017, 60, 2103-2110.	6.3	12
119	The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men. Environmental Research, 2017, 158, 366-372.	7.5	35
120	Higher skin autofluorescence in young people with Type 1 diabetes and microvascular complications. Diabetic Medicine, 2017, 34, 543-550.	2.3	12
121	Progressive Retinal Vasodilation in Patients With Type 1 Diabetes: A Longitudinal Study of Retinal Vascular Geometry. , 2017, 58, 2503.		21
122	Myocardial Production and Release of Stem Cell Factor Following Myocardial Infarction. Journal of Biomaterials and Tissue Engineering, 2017, 7, 77-82.	0.1	2
123	HDL as a Target for Glycemic Control. Current Drug Targets, 2017, 18, 651-673.	2.1	4
124	The Mental Health in Diabetes Service (MINDS) to enhance psychosocial health: study protocol for a randomized controlled trial. Trials, 2016, 17, 444.	1.6	6
125	Elucidating the Biological Mechanisms Linking Depressive Symptoms With Type 2 Diabetes in Men. Psychosomatic Medicine, 2016, 78, 221-232.	2.0	8
126	Time to research Australian female physicianâ€researchers. Internal Medicine Journal, 2016, 46, 412-419.	0.8	7

#	Article	IF	CITATIONS
127	Financial costs for families of children with Type 1 diabetes in lowerâ€income countries. Diabetic Medicine, 2016, 33, 820-826.	2.3	39
128	<scp>QT</scp> interval, corrected for heart rate, is associated with HbA _{1c} concentration and autonomic function in diabetes. Diabetic Medicine, 2016, 33, 1415-1421.	2.3	17
129	Time to research Australian physicianâ€researchers. Internal Medicine Journal, 2016, 46, 550-558.	0.8	14
130	Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study. Critical Care Medicine, 2016, 44, 1695-1703.	0.9	49
131	Nutritional predictors of successful chronic disease prevention for a community cohort in Central Australia. Public Health Nutrition, 2016, 19, 2475-2483.	2.2	4
132	Muscle grip strength predicts incident type 2 diabetes: Population-based cohort study. Metabolism: Clinical and Experimental, 2016, 65, 883-892.	3.4	94
133	Nutritional predictors of chronic disease in a Central Australian Aboriginal cohort: A multi-mixture modelling analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 162-168.	2.6	3
134	Shorter telomeres in adults with Type 1 diabetes correlate with diabetes duration, but only weakly with vascular function and risk factors. Diabetes Research and Clinical Practice, 2016, 117, 4-11.	2.8	17
135	Insulin pump basal adjustment for exercise in type 1 diabetes: a randomised crossover study. Diabetologia, 2016, 59, 1636-1644.	6.3	66
136	Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. Diabetes Technology and Therapeutics, 2016, 18, 772-783.	4.4	77
137	Evolving telehealth reimbursement in Australia. Internal Medicine Journal, 2016, 46, 977-981.	0.8	12
138	Clinical outcomes associated with albuminuria in central Australia: a cohort study. BMC Nephrology, 2016, 17, 113.	1.8	5
139	Feasibility of an Orthogonal Redundant Sensor incorporating Optical plus Redundant Electrochemical Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 679-688.	2.2	7
140	Retinal neuronal and vascular function in type 1 diabetes adults during glycaemic clamps. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 382-384.	1.9	0
141	Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetic Medicine, 2016, 33, 356-364.	2.3	6
142	A single-nucleotide polymorphism in the MicroRNA-146a gene is associated with diabetic nephropathy and sight-threatening diabetic retinopathy in Caucasian patients. Acta Diabetologica, 2016, 53, 643-650.	2.5	53
143	Human islet cells are killed by BID-independent mechanisms in response to FAS ligand. Apoptosis: an International Journal on Programmed Cell Death, 2016, 21, 379-389.	4.9	10
144	Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. Journal of Lipid Research, 2016, 57, 310-317.	4.2	15

#	Article	IF	Citations
145	Data on carotid intima-media thickness and lipoprotein subclasses in type 1 diabetes from the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Data in Brief, 2016, 6, 33-38.	1.0	8
146	Opposite associations between alanine aminotransferase and \hat{l}^3 -glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism: Clinical and Experimental, 2016, 65, 783-793.	3.4	20
147	Circulating microRNA Biomarkers of Diabetic Retinopathy. Diabetes, 2016, 65, 22-24.	0.6	52
148	Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis, 2016, 244, 93-100.	0.8	18
149	Redundancy in Glucose Sensing. Journal of Diabetes Science and Technology, 2016, 10, 669-678.	2.2	14
150	The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research, 2016, 51, 156-186.	15.5	730
151	Substantial and Sustained HbA1c reductions in Australian Insulin Pump Services for Adults with Type 1 Diabetes. Benefit also evident for Older and High HbA1c Subjects. Madridge Journal of Diabetes, 2016, 1, 23-28.	0.1	4
152	Sex Differences in Retinal Microvasculature Through Puberty In Type 1 Diabetes: Are Girls at Greater Risk of Diabetic Microvascular Complications?. Investigative Ophthalmology and Visual Science, 2015, 56, 571-577.	3.3	29
153	Multifocal Pupillography Identifies Changes in Visual Sensitivity According to Severity of Diabetic Retinopathy in Type 2 Diabetes., 2015, 56, 4504.		23
154	Biomarkers in Diabetic Retinopathy. Review of Diabetic Studies, 2015, 12, 159-195.	1.3	198
155	The world I want — a world with less diabetes. Medical Journal of Australia, 2015, 202, 108-109.	1.7	3
156	Lower Urinary Tract Symptoms, Depression, Anxiety and Systemic Inflammatory Factors in Men: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0137903.	2.5	43
157	Trace elements as predictors of preeclampsia in type 1 diabetic pregnancy. Nutrition Research, 2015, 35, 421-430.	2.9	27
158	Arterial elasticity in obese adolescents with clinical features of insulin resistance. Diabetes and Vascular Disease Research, 2015, 12, 62-69.	2.0	2
159	A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Scientific Reports, 2015, 5, 10375.	3.3	64
160	Calibrated integrated backscatter and myocardial fibrosis in patients undergoing cardiac surgery. Open Heart, 2015, 2, e000278.	2.3	15
161	Fish oil and multivitamin supplementation reduces oxidative stress but not inflammation in healthy older adults: A randomised controlled trial. Journal of Functional Foods, 2015, 19, 949-957.	3.4	13
162	The longitudinal association between inflammation and incident depressive symptoms in men: The effects of hs-CRP are independent of abdominal obesity and metabolic disturbances. Physiology and Behavior, 2015, 139, 328-335.	2.1	16

#	Article	IF	Citations
163	Multigenerational Undernutrition Increases Susceptibility to Obesity and Diabetes that Is Not Reversed after Dietary Recuperation. Cell Metabolism, 2015, 22, 312-319.	16.2	83
164	Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema. Ophthalmology, 2015, 122, 1828-1836.	5.2	20
165	Is it Time to Repair a Fairly Fast SAAB Convertible? Testing an Evidence-based Mnemonic for the Secondary Prevention of Cardiovascular Disease. Heart Lung and Circulation, 2015, 24, 480-487.	0.4	4
166	Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 2015, 58, 2035-2044.	6.3	25
167	Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia, 2015, 58, 2288-2297.	6.3	73
168	The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 2015, 58, 464-473.	6.3	78
169	Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes. Diabetes Care, 2015, 38, 521-528.	8.6	127
170	Circulating markers of inflammation and endothelial function, and their relationship to diabetic retinopathy. Diabetic Medicine, 2015, 32, 686-691.	2.3	48
171	Flicker Light-Induced Retinal Vasodilation Is Unaffected by Inhibition of Epoxyeicosatrienoic Acids and Prostaglandins in Humans. Investigative Ophthalmology and Visual Science, 2014, 55, 7007-7013.	3.3	8
172	Sometimes you have to give a man a fish. Medical Journal of Australia, 2014, 200, 122-123.	1.7	2
173	Elevated Circulation Levels of an Antiangiogenic SERPIN in Patients with Diabetic Microvascular Complications Impair Wound Healing through Suppression of Wnt Signaling. Journal of Investigative Dermatology, 2014, 134, 1725-1734.	0.7	54
174	Plasma semicarbazide-sensitive amine oxidase activity in type 1 diabetes is related to vascular and renal function but not to glycaemia. Diabetes and Vascular Disease Research, 2014, 11, 262-269.	2.0	10
175	Clinical correlates of serum pigment epithelium-derived factor in type 2 diabetes patients. Journal of Diabetes and Its Complications, 2014, 28, 353-359.	2.3	19
176	Lipoprotein Glycation in Diabetes Mellitus. Contemporary Diabetes, 2014, , 157-186.	0.0	1
177	About Randomised Clinical Trials Related to Lipoproteins in Diabetes Mellitus. Contemporary Diabetes, 2014, , 329-346.	0.0	0
178	Emerging Lipoprotein-Related Therapeutics for Patients with Diabetes. Contemporary Diabetes, 2014, , 435-453.	0.0	0
179	Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia, 2014, 57, 2296-2303.	6.3	43
180	Genetic study of diabetic retinopathy: recruitment methodology and analysis of baseline characteristics. Clinical and Experimental Ophthalmology, 2014, 42, 486-493.	2.6	14

#	Article	IF	Citations
181	An exploratory trial of basal and prandial insulin initiation and titration for type 2 diabetes in primary care with adjunct retrospective continuous glucose monitoring: INITIATION study. Diabetes Research and Clinical Practice, 2014, 106, 247-255.	2.8	22
182	HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes. Diabetes Care, 2014, 37, 2351-2358.	8.6	50
183	Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: A prospective study. Atherosclerosis, 2014, 236, 188-195.	0.8	27
184	An exploratory trial of insulin initiation and titration among patients with type 2 diabetes in the primary care setting with retrospective continuous glucose monitoring as an adjunct: INITIATION study protocol. BMC Family Practice, 2014, 15, 82.	2.9	8
185	Peroxisome Proliferator–Activated Receptor α Protects Capillary Pericytes in the Retina. American Journal of Pathology, 2014, 184, 2709-2720.	3.8	71
186	Cohort Profile: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study. International Journal of Epidemiology, 2014, 43, 1040-1053.	1.9	53
187	The Incretin Response After Successful Islet Transplantation. Transplantation, 2014, 97, e9-e11.	1.0	5
188	Response to the Letter by Kawada et al. regarding the manuscript entitled "The metabolic syndrome and CVD outcomes for a central Australian cohort― Diabetes Research and Clinical Practice, 2013, 102, e22-e23.	2.8	0
189	Immune cell-mediated inflammation and the early improvements in glucose metabolism after gastric banding surgery. Diabetologia, 2013, 56, 2564-2572.	6.3	19
190	Psychosocial issues of women with type 1 diabetes transitioning to motherhood: a structured literature review. BMC Pregnancy and Childbirth, 2013, 13, 218.	2.4	34
191	Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis, 2013, 231, 315-322.	0.8	34
192	Apolipoprotein-defined lipoproteins and apolipoproteins: Associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. Journal of Diabetes and Its Complications, 2013, 27, 447-453.	2.3	9
193	An Update on the Molecular Actions of Fenofibrate and Its Clinical Effects on Diabetic Retinopathy and Other Microvascular End Points in Patients With Diabetes. Diabetes, 2013, 62, 3968-3975.	0.6	97
194	Apolipoprotein-defined and NMR lipoprotein subclasses in the Veterans Affairs Diabetes Trial. Journal of Diabetes and Its Complications, 2013, 27, 627-632.	2.3	5
195	Reduced microvascular density in non-ischemic myocardium of patients with recent non-ST-segment-elevation myocardial infarction. International Journal of Cardiology, 2013, 167, 1027-1037.	1.7	21
196	The metabolic syndrome and CVD outcomes for a central Australian cohort. Diabetes Research and Clinical Practice, 2013, 100, e70-e73.	2.8	8
197	Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models. Diabetes, 2013, 62, 261-272.	0.6	148
198	Serum Inflammatory Markers and Preeclampsia in Type 1 Diabetes. Diabetes Care, 2013, 36, 2054-2061.	8.6	29

#	Article	IF	Citations
199	Advanced Glycation End Products Acutely Impair Ca2+ Signaling in Bovine Aortic Endothelial Cells. Frontiers in Physiology, 2013, 4, 38.	2.8	18
200	Reduced arterial stiffness after weight loss in obese type 2 diabetes and impaired glucose tolerance: The role of immune cell activation and insulin resistance. Diabetes and Vascular Disease Research, 2013, 10, 40-48.	2.0	26
201	Feasibility of Adjacent Insulin Infusion and Continuous Glucose Monitoring via the Medtronic Combo-Set. Journal of Diabetes Science and Technology, 2013, 7, 381-388.	2.2	14
202	Telehealth in Australia: an evolution in health care services. Medical Journal of Australia, 2013, 199, 23-24.	1.7	16
203	Apolipoprotein A-I glycation by Glucose and Reactive Aldehydes Alters Phospholipid Affinity but Not Cholesterol Export from Lipid-Laden Macrophages. PLoS ONE, 2013, 8, e65430.	2.5	33
204	Benefits and Safety of Long-Term Fenofibrate Therapy in People With Type 2 Diabetes and Renal Impairment. Diabetes Care, 2012, 35, 218-225.	8.6	108
205	Plasma Lipoproteins and Preeclampsia in Women with Type 1 Diabetes: A Prospective Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1752-1762.	3.6	22
206	Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4701-4708.	3.6	72
207	Retinal Vascular Geometry Predicts Incident Renal Dysfunction in Young People With Type 1 Diabetes. Diabetes Care, 2012, 35, 599-604.	8.6	46
208	Serum Apolipoproteins Are Associated With Systemic and Retinal Microvascular Function in People With Diabetes. Diabetes, 2012, 61, 1785-1792.	0.6	31
209	Plantar Fascia Thickness is Longitudinally Associated with Retinopathy and Renal Dysfunction: A Prospective Study from Adolescence to Adulthood. Journal of Diabetes Science and Technology, 2012, 6, 348-355.	2.2	16
210	Normalized NEFA Dynamics During an OGTT After Islet Transplantation. Transplantation, 2012, 94, e49-e51.	1.0	8
211	Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: Assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Research and Clinical Practice, 2012, 95, e17-e19.	2.8	25
212	Reduced soluble receptor for advanced glycation endâ€products (sRAGE) scavenger capacity precedes preâ€eclampsia in Type 1 diabetes. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 1512-1520.	2.3	15
213	Retinal Arteriolar Tortuosity is Associated With Retinopathy and Early Kidney Dysfunction in Type 1 Diabetes. American Journal of Ophthalmology, 2012, 153, 176-183.e1.	3.3	80
214	Diastolic Dysfunction of Aging Is Independent of Myocardial Structure but Associated with Plasma Advanced Glycation End-Product Levels. PLoS ONE, 2012, 7, e49813.	2.5	44
215	High Concentrations of AGE-LDL and Oxidized LDL in Circulating Immune Complexes Are Associated With Progression of Retinopathy in Type 1 Diabetes. Diabetes Care, 2012, 35, 1333-1340.	8.6	59
216	Telemedicine and ocular health in diabetes mellitus. Australasian journal of optometry, The, 2012, 95, 311-327.	1.3	30

#	Article	IF	CITATIONS
217	Nonâ€invasive measures of tissue autofluorescence are increased in Type 1 diabetes complications and correlate with a nonâ€invasive measure of vascular dysfunction. Diabetic Medicine, 2012, 29, 726-733.	2.3	44
218	Novel versus traditional risk markers for diabetic retinopathy. Diabetologia, 2012, 55, 666-670.	6.3	37
219	Differences in Myocardial Structure and Coronary Microvasculature Between Men and Women With Coronary Artery Disease. Hypertension, 2011, 57, 186-192.	2.7	45
220	Prosthetic valve endocarditis: what is the evidence for anticoagulant therapy?. Internal Medicine Journal, 2011, 41, 795-797.	0.8	12
221	Young adults' management of Type 1 diabetes during life transitions. Journal of Clinical Nursing, 2011, 20, 1981-1992.	3.0	59
222	Comparing Effects of a Low-energy Diet and a High-protein Low-fat Diet on Sexual and Endothelial Function, Urinary Tract Symptoms, and Inflammation in Obese Diabetic Men. Journal of Sexual Medicine, 2011, 8, 2868-2875.	0.6	128
223	LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. Journal of Diabetes and Its Complications, 2011, 25, 73-82.	2.3	9
224	Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia, 2011, 54, 280-290.	6.3	304
225	Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovascular Diabetology, 2011, 10, 80.	6.8	47
226	Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man. Journal of Translational Medicine, 2011, 9, 150.	4.4	29
227	Retinal Vascular Geometry Predicts Incident Retinopathy in Young People With Type 1 Diabetes. Diabetes Care, 2011, 34, 1622-1627.	8.6	81
228	Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoproteins Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1192-1200.	2.4	37
229	Serum Apolipoprotein Al and B Are Stronger Biomarkers of Diabetic Retinopathy Than Traditional Lipids. Diabetes Care, 2011, 34, 474-479.	8.6	116
230	Serum Carotenoids and Fat-Soluble Vitamins in Women With Type 1 Diabetes and Preeclampsia. Diabetes Care, 2011, 34, 1258-1264.	8.6	60
231	An Algorithm Guiding Patient Responses to Real-Time-Continuous Glucose Monitoring Improves Quality of Life. Diabetes Technology and Therapeutics, 2011, 13, 105-109.	4.4	21
232	Improved Second Phase Insulin Secretion and Preserved Insulin Sensitivity After Islet Transplantation. Transplantation, 2010, 89, 1291-1292.	1.0	4
233	Increased tissue kallikrein levels in type 2 diabetes. Diabetologia, 2010, 53, 779-785.	6.3	33
234	Thioflavin T fluorescence in human serum: Correlations with vascular health and cardiovascular risk factors. Clinical Biochemistry, 2010, 43, 278-286.	1.9	8

#	Article	IF	Citations
235	Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. Journal of Angiogenesis Research, 2010, 2, 19.	2.9	38
236	Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and veryâ€lowâ€density lipoprotein particle concentrations in statinâ€treated type 2 diabetic patients. Diabetes, Obesity and Metabolism, 2010, 12, 752-756.	4.4	32
237	Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 766-772.	2.4	125
238	Alterations in Retinal Microvascular Geometry in Young Type 1 Diabetes. Diabetes Care, 2010, 33, 1331-1336.	8.6	128
239	Why should a doctor be interested in oral disease? Expert Review of Cardiovascular Therapy, 2010, 8, 1483-1493.	1.5	18
240	Evaluation of an Algorithm to Guide Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion on How to Respond to Real-Time Continuous Glucose Levels: A randomized controlled trial. Diabetes Care, 2010, 33, 1242-1248.	8.6	25
241	Associations among smoking status, lifestyle and lipoprotein subclasses. Journal of Clinical Lipidology, 2010, 4, 522-530.	1.5	11
242	NMR-determined lipoprotein subclass profile is associated with dietary composition and body sizeâ ⁺ . Nutrition, Metabolism and Cardiovascular Diseases, 2010, 21, 603-9.	2.6	12
243	Glycated proteins inhibit K channels in isolated vascular smooth muscle cells. FASEB Journal, 2010, 24, 976.3.	0.5	0
244	Effect of advanced glycation end products on dilation of rat skeletal muscle arterioles. FASEB Journal, 2010, 24, lb566.	0.5	0
245	Position statement of the Australian Diabetes Society: individualisation of glycated haemoglobin targets for adults with diabetes mellitus. Medical Journal of Australia, 2009, 191, 339-344.	1.7	58
246	Lipid treatment guidelines and cardiovascular risk for Aboriginal people in Central Australia. Medical Journal of Australia, 2009, 190, 552-556.	1.7	7
247	Retinal Vascular Fractal Dimension and Risk of Early Diabetic Retinopathy. Diabetes Care, 2009, 32, 2081-2083.	8.6	60
248	C-Reactive Protein Concentrations Are Very High and More Stable over Time Than the Traditional Vascular Risk Factors Total Cholesterol and Systolic Blood Pressure in an Australian Aboriginal Cohort. Clinical Chemistry, 2009, 55, 336-341.	3.2	14
249	Quantitative Assessment of Early Diabetic Retinopathy Using Fractal Analysis. Diabetes Care, 2009, 32, 106-110.	8.6	179
250	Is nuclear magnetic resonance lipoprotein subclass related to diabetic retinopathy? The multi-ethnic study of atherosclerosis (MESA). Diabetes and Vascular Disease Research, 2009, 6, 40-42.	2.0	4
251	Anti-angiogenic factors and pre-eclampsia in type 1 diabetic women. Diabetologia, 2009, 52, 160-168.	6.3	53
252	Increased coatedâ€platelet levels in chronic haemodialysis patients. Nephrology, 2009, 14, 148-154.	1.6	20

#	Article	IF	CITATIONS
253	Elevated plasma prostaglandins and acetylated histone in monocytes in TypeÂ1 diabetes patients. Diabetic Medicine, 2009, 26, 182-186.	2.3	37
254	NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diabetes Research and Clinical Practice, 2009, 83, 132-139.	2.8	45
255	Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. Journal of Diabetes and Its Complications, 2008, 22, 153-163.	2.3	24
256	Glutathionyl haemoglobin is not increased in diabetes nor related to glycaemia, complications, dyslipidaemia, inflammation or other measures of oxidative stress. Diabetes Research and Clinical Practice, 2008, 80, e1-e3.	2.8	16
257	Coated-platelet levels in patients with Type 1 and with Type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2008, 81, e8-e10.	2.8	36
258	Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. Diabetes Research and Clinical Practice, 2008, 82, e5-e7.	2.8	68
259	Australian Aboriginal people and Torres Strait Islanders have an atherogenic lipid profile that is characterised by low HDL-cholesterol level and small LDL particles. Atherosclerosis, 2008, 201, 368-377.	0.8	25
260	Association Between p.Leu54Met Polymorphism at the Paraoxonase-1 Gene and Plantar Fascia Thickness in Young Subjects With Type 1 Diabetes. Diabetes Care, 2008, 31, 1585-1589.	8.6	10
261	Plasminogen Activator Inhibitor-1 Activity in Type 2 Diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 786-791.	2.4	42
262	Risk Factors Related to Inflammation and Endothelial Dysfunction in the DCCT/EDIC Cohort and Their Relationship With Nephropathy and Macrovascular Complications. Diabetes Care, 2008, 31, 2006-2012.	8.6	90
263	Retinal Arteriolar Dilation Predicts Retinopathy in Adolescents With Type 1 Diabetes. Diabetes Care, 2008, 31, 1842-1846.	8.6	118
264	Increased methionine sulfoxide content of apoA-I in type 1 diabetes. Journal of Lipid Research, 2008, 49, 847-855.	4.2	48
265	Lower than expected morbidity and mortality for an Australian Aboriginal population: 10â€year followâ€up in a decentralised community. Medical Journal of Australia, 2008, 188, 283-287.	1.7	100
266	Diabetes and Oxidant Stress. , 2008, , 123-158.		1
267	Longitudinal analysis of low-molecular weight fluorophores in type 1 diabetes mellitus. Journal of Medical Investigation, 2008, 55, 29-36.	0.5	5
268	Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 413-418.	2.8	6
269	Oral Glucosamine in Doses Used to Treat Osteoarthritis Worsens Insulin Resistance. American Journal of the Medical Sciences, 2007, 333, 333-339.	1.1	48
270	Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. Journal of Hypertension, 2007, 25, 699-705.	0.5	8

#	Article	IF	Citations
271	Cardiovascular risk factors in pre-pubertal Malays: Effects of diabetic parentage. Diabetes Research and Clinical Practice, 2007, 76, 119-125.	2.8	11
272	Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. Atherosclerosis, 2007, 190, 359-369.	0.8	66
273	Widespread vascular production of C-reactive protein (CRP) and a relationship between serum CRP, plaque CRP and intimal hypertrophy. Atherosclerosis, 2007, 191, 175-181.	0.8	37
274	Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in TypeÂ1 diabetes. Diabetic Medicine, 2007, 24, 1345-1351.	2.3	72
275	The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. Australian and New Zealand Journal of Obstetrics and Gynaecology, 2007, 47, 186-190.	1.0	65
276	The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia, 2007, 50, 643-653.	6.3	122
277	Effects of D- and L-Glucose and Mannitol on Retinal Capillary Cells: Inhibition by Nanomolar Aminoguanidine. American Journal of Pharmacology and Toxicology, 2007, 2, 148-158.	0.7	8
278	Retinal Vascular Caliber and Risk of Retinopathy in Young Patients with Type 1 Diabetes. Ophthalmology, 2006, 113, 1499-1503.	5.2	76
279	Soluble Vascular Cell Adhesion Molecule 1 and N-terminal Pro–B-Type Natriuretic Peptide in Predicting Ischemic Stroke in Patients With Cerebrovascular Disease. Archives of Neurology, 2006, 63, 60.	4.5	41
280	Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness. Diabetic Medicine, 2006, 23, 955-966.	2.3	54
281	Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Internal Medicine Journal, 2006, 36, 237-243.	0.8	42
282	Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes. Diabetologia, 2006, 49, 2488-2498.	6.3	55
283	Association between PON 1 polymorphisms, PON activity and diabetes complications. Journal of Diabetes and Its Complications, 2006, 20, 322-328.	2.3	57
284	Do adiponectin, TNFα, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes/Metabolism Research and Reviews, 2006, 22, 131-138.	4.0	144
285	High density lipoproteins bind $\hat{Al^2}$ and apolipoprotein C-II amyloid fibrils. Journal of Lipid Research, 2006, 47, 755-760.	4.2	15
286	Exercise frequency and arterial compliance in non-diabetic and type 1 diabetic individuals. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 598-603.	2.8	22
287	Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Clinical Science, 2005, 108, 497-506.	4.3	31
288	A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochemical Journal, 2005, 390, 427-436.	3.7	60

#	Article	IF	CITATIONS
289	Glycation Does Not Alter LDL-Induced Secretion of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 from Human Aortic Endothelial Cells. Annals of the New York Academy of Sciences, 2005, 1043, 379-389.	3.8	6
290	Lipidâ€Derived Modifications of Plasma Proteins in Experimental and Human Diabetes. Annals of the New York Academy of Sciences, 2005, 1043, 404-412.	3.8	5
291	Plasma Low-Molecular Weight Fluorescence in Type 1 Diabetes Mellitus. Annals of the New York Academy of Sciences, 2005, 1043, 655-661.	3.8	13
292	Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes. Journal of Diabetes and Its Complications, 2005, 19, 18-25.	2.3	31
293	Paraoxonase activity in Greek migrants and Anglo–Celtic persons in the Melbourne Collaborative Cohort Study: relationship to dietary markers. European Journal of Nutrition, 2005, 44, 223-230.	3.9	11
294	Chemical modification of proteins during peroxidation of phospholipids. Journal of Lipid Research, 2005, 46, 1440-1449.	4.2	34
295	Associations Between Liver Histology and Severity of the Metabolic Syndrome in Subjects With Nonalcoholic Fatty Liver Disease. Diabetes Care, 2005, 28, 1222-1224.	8.6	103
296	Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial. Circulation, 2005, 111, 2446-2453.	1.6	95
297	The vascular endothelium in diabetes: a practical target fordrug treatment?. Expert Opinion on Therapeutic Targets, 2005, 9, 101-117.	3.4	20
298	Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease. Circulation, 2005, 112, 110-116.	1.6	71
299	Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease. Hypertension, 2005, 45, 69-74.	2.7	39
300	Associations of Inflammatory and Hemostatic Variables With the Risk of Recurrent Stroke. Stroke, 2005, 36, 2143-2147.	2.0	123
301	Systemic and vascular inflammation is elevated in early IgA and type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrology Dialysis Transplantation, 2005, 20, 2420-2426.	0.7	54
302	Critical Evaluation of Adult Treatment Panel III Criteria in Identifying Insulin Resistance With Dyslipidemia. Diabetes Care, 2004, 27, 978-983.	8.6	186
303	Diabetic Retinopathy and Serum Lipoprotein Subclasses in the DCCT/EDIC Cohort., 2004, 45, 910.		266
304	The STATs in cell stress-type responses. Cell Communication and Signaling, 2004, 2, 8.	6.5	41
305	â€~Lipoproteins, glycoxidation and diabetic angiopathy'. Diabetes/Metabolism Research and Reviews, 2004, 20, 349-368.	4.0	85
306	In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes. Metabolism: Clinical and Experimental, 2004, 53, 969-976.	3.4	16

#	Article	IF	Citations
307	Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: Associations with lipoprotein subclasses. Metabolism: Clinical and Experimental, 2004, 53, 1296-1304.	3.4	31
308	Comparison of arterial assessments in low and high vascular disease risk groups. American Journal of Hypertension, 2004, 17, 285-291.	2.0	61
309	Lipoproteins and Diabetic Microvascular Complications. Current Pharmaceutical Design, 2004, 10, 3395-3418.	1.9	87
310	Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis and Rheumatism, 2003, 48, 81-89.	6.7	183
311	Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathy. Kidney International, 2003, 64, 817-828.	5.2	173
312	Octreotide treatment of severe diabetic diarrhoea. Internal Medicine Journal, 2003, 33, 617-618.	0.8	12
313	Value of the micropig model of menopause in the assessment of benefits and risks of postmenopausal therapies for cardiovascular and reproductive tissues*1. Fertility and Sterility, 2003, 79, 779-788.	1.0	10
314	STI-571 inhibits in vitro angiogenesis. Biochemical and Biophysical Research Communications, 2003, 310, 135-142.	2.1	16
315	A Cross-Sectional Study of the Effects of Type 2 Diabetes and Other Cardiovascular Risk Factors on Structure and Function of Nonstenotic Arteries of the Lower Limb. Diabetes Care, 2003, 26, 199-205.	8.6	31
316	Fibrinogen Is a Marker for Nephropathy and Peripheral Vascular Disease in Type 1 Diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care, 2003, 26, 1439-1448.	8.6	62
317	Serum Lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: Associations with gender and glycemia. Diabetes Care, 2003, 26, 810-818.	8.6	104
318	Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance. Diabetes, 2003, 52, 453-462.	0.6	539
319	Lipoprotein abnormalities in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 245-250.	0.6	1
320	Low plasma concentrations of diet-derived antioxidants in association with microalbuminuria in Indigenous Australian populations. Clinical Science, 2003, 105, 569-575.	4.3	15
321	Inflammation and vascular endothelial activation in an Aboriginal population: relationships to coronary disease risk factors and nutritional markers. Medical Journal of Australia, 2003, 178, 495-500.	1.7	73
322	Paraoxonase and other coronary risk factors in a community-based cohort. Redox Report, 2002, 7, 304-307.	4.5	11
323	Advanced glycation end products and diabetic complications. Expert Opinion on Investigational Drugs, 2002, 11, 1205-1223.	4.1	121
324	Novel agents for managing dyslipidaemia. Expert Opinion on Investigational Drugs, 2001, 10, 1901-1911.	4.1	8

#	Article	IF	CITATIONS
325	Isotope Dilution Gas Chromatography/Mass Spectrometry Method for the Determination of Methionine Sulfoxide in Protein. Analytical Chemistry, 2001, 73, 4662-4667.	6.5	32
326	Activation of MAPK by modified low-density lipoproteins in vascular smooth muscle cells. Journal of Applied Physiology, 2001, 91, 1412-1420.	2.5	43
327	Native and modified LDL activate extracellular signal-regulated kinases in mesangial cells. Diabetes, 2000, 49, 2160-2169.	0.6	60
328	Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions. Journal of Biological Chemistry, 2000, 275, 21177-21184.	3.4	220
329	Aminoguanidine and the effects of modified LDL on cultured retinal capillary cells. Investigative Ophthalmology and Visual Science, 2000, 41, 1176-80.	3.3	24
330	Quantification of N-(Glucitol)ethanolamine and N-(Carboxymethyl)serine: Two Products of Nonenzymatic Modification of Aminophospholipids Formed in Vivo. Analytical Biochemistry, 1999, 272, 48-55.	2.4	29
331	Pre-enrichment of modified low density lipoproteins with a-tocopherol mitigates adverse effects on cultured retinal capillary cells. Current Eye Research, 1999, 19, 137-145.	1.5	17
332	Carboxymethylethanolamine, a Biomarker of Phospholipid Modification during the Maillard Reaction in Vivo. Journal of Biological Chemistry, 1997, 272, 17473-17479.	3.4	91
333	Lipoprotein glycation and its metabolic consequences. Current Opinion in Lipidology, 1997, 8, 174-180.	2.7	150
334	Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoprotein. Biochemical Journal, 1997, 322, 317-325.	3.7	275
335	Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis. Diabetes Reviews, 1997, 5, 365-391.	0.0	31
336	The Advanced Glycation End Product, Nâ´Š-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions. Journal of Biological Chemistry, 1996, 271, 9982-9986.	3.4	676
337	LDL From Patients With Well-Controlled IDDM Is Not More Susceptible to In Vitro Oxidation. Diabetes, 1996, 45, 762-767.	0.6	56
338	LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes, 1996, 45, 762-767.	0.6	20
339	The role of lipoprotein(a) in the vascular complications of diabetes mellitus. Journal of Internal Medicine, 1995, 237, 359-365.	6.0	25
340	Irish endocrine society. Irish Journal of Medical Science, 1992, 161, 423-427.	1.5	0
341	Plasma apolipoprotein (a) is increased in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia, 1992, 35, 1055-1059.	6.3	78
342	Increased Plasma Apolipoprotein(a) Levels in IDDM Patients With Microalbuminuria. Diabetes, 1991, 40, 787-790.	0.6	119

ALICIA J JENKINS

#	Article	IF	CITATIONS
343	Snapshot of CGM metrics in adolescents and adults achieving target HbA1c versus those not meeting target HbA1c Diabetes Technology and Therapeutics, 0, , .	4.4	O